PATENT CLAIM ANALYSIS

Application Number: 16045855
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-05
Patent Classification: ["514", "054000"]

Abstract:
The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.

Claim (Index 45):
The compound according to  claim 44  wherein A is

Metadata:
- Claim Count in Document: 53.0
- Percentile: 95.0
- Lexical Diversity: 1.5
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14480204', '15083025', '13173480', '12991926', '14397995']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7936246703457767
- 35 USC 102 Novelty (BERT): 0.5619940793118822
- Combined Prediction Score: 0.7704616112423872
- Mean Citation Score: 397.042508
- Max Citation Score: 436.78046
- Similarity Product: 327.59552435036784

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test